Lb Pharmaceuticals (LBRX) Capital Expenditures (2024 - 2026)

Lb Pharmaceuticals' Capital Expenditures history runs 3 years deep, the most recent figure standing at $32000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures rose 52.38% year-over-year to $32000.0; the TTM figure through Mar 2026 stood at $331000.0 (changed N/A YoY), while the FY2025 annual figure was $52000.0, down 93.24% from the prior year.
• Capital Expenditures was $32000.0 for Q1 2026 at Lb Pharmaceuticals, down from $40000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $238000.0 in Q4 2024 to a low of $21000.0 in Q1 2025.
• Historically, Capital Expenditures has averaged $82750.0 across 3 years, with a median of $36000.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Capital Expenditures plunged 83.19% in 2025, then jumped 52.38% in 2026.
• A 3-year view of Capital Expenditures shows it stood at $238000.0 in 2024, then tumbled by 83.19% to $40000.0 in 2025, then dropped by 20.0% to $32000.0 in 2026.
• The last three Capital Expenditures figures came in at $32000.0 (Q1 2026), $40000.0 (Q4 2025), and $21000.0 (Q1 2025), per Business Quant data.